Durvalumab plus carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status

被引：0

作者：

Van Nieuwenhuysen, Els

Baurain, Jean-Francois

Chon, Hye Sook

Pepin, Jessica Thomes

Sundborg, Michael J.

Gold, Michael A.

Kim, Byoung-Gie

Blank, Stephanie V.

Liu, Ji-Hong

McCollum, Michael

Mori, Masahiko

Jonuskiene, Goda

Moore, Kathleen N.

Novak, Zoltan

Ramos, Pedro

Andree, Charles

de Padua, Joseph

Gil-Martin, Marta

Kowgier, Matthew

del Rosario, Paula Michelle

Westin, Shannon Neville

机构：

[1] UZ Leuven, Leuven, Belgium

[2] BGOG, Leuven, Belgium

[3] Clin Univ St Luc, Med Oncol Unit, Brussels, Belgium

[4] BGOG, Brussels, Belgium

[5] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] Minnesota Oncol, Maplewood, MN USA

[7] FirstHlth Moore Reg Hosp, Pinehurst, NC USA

[8] Oklahoma Canc Specialists & Res Inst, Tulsa, OK USA

[9] Sungkyunkwan Univ, Dept Obstet & Gynecol, Samsung Med Ctr, Sch Med, Seoul, South Korea

[10] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[11] GOG Fdn GOG F, New York, NY USA

[12] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China

[13] Virginia Oncol Associates, Brock Canc Ctr, Norfolk, VA USA

[14] GOG Fdn GOG F, Norfolk, VA USA

[15] Aichi Canc Ctr Hosp, Dept Gynecol Oncol, Nagoya, Aichi, Japan

[16] Vilnius Univ Hosp, Santaros Clin, Vilnius, Lithuania

[17] NSGO, Vilnius, Lithuania

[18] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[19] Natl Inst Oncol, Budapest, Hungary

[20] Cent & Eastern European Gynecol Oncol Grp CEEGOG, Budapest, Hungary

[21] Ctr Cirugia Minima Invasiva, Cecimin, Bogota, Colombia

[22] Cetus Med Oncol, Belo Horizonte, MG, Brazil

[23] Catalan Inst Oncol, Dept Med Oncol, Inst Invest Biomed Bellvitge IDIBELL, Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain

[24] GEICO, Barcelona, Spain

[25] AstraZeneca, Oncol Biometr, Mississauga, ON, Canada

[26] AstraZeneca, Oncol R&D, Global Med Dev, Cambridge, England

[27] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5595

引用

页数：1

共 28 条

[1] Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Westin, Shannon N.
Moore, Kathleen
Chon, Hye Sook
Lee, Jung-Yun
Pepin, Jessica Thomes
Sundborg, Michael
Shai, Ayelet
de la Garza, Joseph
Nishio, Shin
Gold, Michael A.
Wang, Ke
Mcintyre, Kristi
Tillmanns, Todd D.
Blank, Stephanie V.
Liu, Ji-Hong
Mccollum, Michael
Mejia, Fernando Contreras
Nishikawa, Tadaaki
Pennington, Kathryn
Novak, Zoltan
De Melo, Andreia Cristina
Sehouli, Jalid
Klasa-Mazurkiewicz, Dagmara
Papadimitriou, Christos
Gil-Martin, Marta
Brasiuniene, Birute
Donnelly, Conor
del Rosario, Paula Michelle
Liu, Xiaochun
Van Nieuwenhuysen, Els
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (03) : 283 - 299
[2] Durvalumab plus carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Blank, S. V.
McCollum, M.
Anderson, C.
Pennington, K.
Salinas, E.
Richardson, D. L.
Slomovitz, B. M.
Kim, B-G.
Liu, J.
Mori, M.
Guette, P. L. Ramos
de Padua, C. Joseph
Martinez-Garcia, J.
Papadimitriou, C.
Grisan, K.
Poka, R. L.
Kowgier, M.
Del Rosario, P. M. D.
Van Nieuwenhuysen, E.
Westin, S.
ANNALS OF ONCOLOGY, 2024, 35 : S557 - S557
[3] Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial
Westin, Shannon N.
Moore, Kathleen N.
Chon, Hye Sook
Lee, Jung-Yun
Pepin, Jessica Thomes
Sundborg, Michael
Garza, Joseph De La
Nishio, Shin
Wang, Ke
Mcintyre, Kristi
Tillmanns, Todd D.
Mejia, Fernando Contreras
Melo, Andreia Cristina De
Klasa-Mazurkewicz, Dagmara
Papadimitriou, Christos
Gil-Martin, Marta
Brasiuniene, Birute
Donnelly, Conor
Liu, Xiaochun
Nieuwenhuysen, Els Van
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A24 - A25
[4] Safety and tolerability of durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.
Pepin, Jessica Thomes
Chon, Hye Sook
Sundborg, Michael J.
Gold, Michael A.
Kim, Byoung-Gie
Blank, Stephanie V.
Liu, Ji-Hong
McCollum, Michael
Mori, Masahiko
Moore, Kathleen N.
Diaz, Julian Rivera
de Padua, Charles Andree Joseph
Martinez-Garcia, Jeronimo
Papadimitriou, Christos
Grian, Karin
Poka, Robert
Kowgier, Matthew
Oscroft, Emma
Van Nieuwenhuysen, Els
Westin, Shannon Neville
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Erratum: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial (Oct,10.1200/JCO.23.02132,2023)
Westin, Shannon N.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (27) : 3262 - 3262
[6] Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial
Westin, S. N.
Moore, K. N.
Chon, H. S.
Lee, J. Y.
Pepin, J. Thomes
Sundborg, M.
De la Garza, J.
Nishio, S.
Wang, K.
Mcintyre, K.
Tillmanns, T.
Mejia, F. Contreras
De Melo, A. C.
Klasa-Mazurkiewicz, D.
Papadimitriou, C. A.
Martin, M. Gil
Brasiuniene, B.
Donnelly, C.
Liu, X.
Van Nieuwenhuysen, E.
ANNALS OF ONCOLOGY, 2023, 34 : S1282 - S1283
[7] Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial
Harter, Philipp
Wimberger, Pauline
Okamoto, Aikou
Reuss, Alexander
Lim, Myong Cheol
Rubio-Perez, Maria Jesus
Vardar, Mehmet Ali
Scambia, Giovanni
Tredan, Olivier
Hietanen, Sakari
Colombo, Nicoletta
Chudecka-Glaz, Anita
Petru, Edgar
Lheureux, Stephanie
Van Nieuwenhuysen, Els
Sehouli, Jalid
Wenham, Robert
Ushijima, Kimio
Indiviglio, Sandra
Aghajanian, Carol
GYNECOLOGIC ONCOLOGY, 2024, 190 : S65 - S66
[8] Safety and tolerability of durvalumab (D) plus carboplatin/paclitaxel (CP) plus bevacizumab (B) followed by D, B plus olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
Aghajanian, C.
Schmalfeldt, B.
Okamoto, A.
Reuss, A.
Kim, J-W.
Ospina, G. Marquina
Ayhan, A.
Salutari, V.
Lebreton, C.
Labudovic, D.
Tognon, G.
Chudecka-Glaz, A. M.
Berger, R.
Lheureux, S.
Henry, S.
Burges, A.
Wenham, R. M.
Nishio, S.
Marshall, L.
Harter, P.
ANNALS OF ONCOLOGY, 2024, 35 : S570 - S571
[9] Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib for endometrial cancer: mismatch repair deficient and/or microsatellite instability-high subpopulation efficacy analyses from the DUO-E trial
Nieuwenhuysen, Els Van
Moore, Kathleen
Tillmanns, Todd
Haygood, Christen
Chambers, Setsuko
Priebe, Anna
Kim, Young
Slomovitz, Brian
Jonuskiene, Goda
Barretina-Ginesta, Maria Pilar
Tibor, Csoszi
Zagouri, Flora
Kim, Jae-Weon
Gao, Qinglei
Mejia, Fernando Contreras
Melo, Andreia Cristina De
Nishikawa, Tadaaki
Kowgier, Matthew
Wang, Vivian Ying
Westin, Shannon
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A2 - A3
[10] DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
Westin, Shannon Neville
Moore, Kathleen N.
Van Nieuwenhuysen, Els
Oza, Amit M.
Mileshkin, Linda R.
Okamoto, Aikou
Suzuki, Akiko
Meyer, Kassondra
Barker, Laura
Rhee, Joon
Vergote, Ignace
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 →